GALMED PHARMACEUTICALS LTD.

Analyst Reco. Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-03 EDT			5-day change	1st Jan Change
0.3874 ^USD	+0.60%		-1.07%	-14.86%

04-04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-15	Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4	23-07-24	MT
Maxim Group Downgrades Galmed Pharmaceuticals to Hold From Buy	22-08-08	MT
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5	22-08-08	MT
Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5	22-08-04	MT
Galmed Pharmaceuticals Shares Fall After Rating Downgrade From Raymond James	22-05-18	MT
Raymond James Downgrades Galmed Pharmaceuticals to Market Perform From Outperform	22-05-18	MT
HC Wainwright Downgrades Galmed Pharmaceuticals to Neutral From Buy	22-05-03	MT
Raymond James Adjusts Price Target on Galmed Pharmaceuticals to $5 From $14, Keeps Outperform Rating	22-05-03	MT
GALMED PHARMACEUTICALS : HC Wainwright & Co. Adjusts Price Target on Galmed Pharmaceuticals to $25 From $29, Maintains Buy Rating	21-03-19	MT
GALMED PHARMACEUTICALS : Canaccord Genuity Adjusts Price Target on Galmed Pharmaceuticals to $20 From $25, Maintains Buy Rating	20-11-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer